GLP-1s are driving returns on R&D investments for Big Pharma, report says [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Deloitte's annual report, Measuring the Return from Pharmaceutical Innovation , found that GLP-1 drugs could fuel significant returns on research and development investments made last year by major drugmakers. The consulting firm analyzed the projected internal rate of return for late-stage pipeline assets across the 20 leading pharma companies. On average, these companies forecast peak sales of $510 million per asset. But when GLP-1s are excluded, that figure drops sharply to $370 million. The internal rate of return for late-stage pipeline assets climbed from 5.9% in 2024, from 4.1% in 2023 — again driven in large part by GLP-1 drugs. Without them, returns would have declined, dipping to 3.8% in 2024 and 3.4% in 2023. This matters even more given that the report also found that the average cost to develop a drug for Big Pharma was $2.23 billion in 2024, up from $2.12 billion the year before. GLP-1 drugs mimic hormones that regulate blood sugar and suppress appetite, making th
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly (LLY) Gains Support From Daiwa and Goldman Sachs in Back-to-Back Calls [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Market Voices: Lilly's new obesity pill, NYSE owner eyes crypto firm [Seeking Alpha]Seeking Alpha
- Why Eli Lilly (LLY) Stock Is Trading Up Today [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (NYSE:LLY) had its "neutral" rating reaffirmed by analysts at UBS Group AG.MarketBeat
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- LLY's page on the SEC website